Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Acorda Drops Epilepsy Candidate Once Central To Its Revenue Forecasts

Executive Summary

Plumiaz, a nasal spray formulation of diazepam, is discontinued after it fails one of three Phase III trials undertaken to comply with 2014 FDA complete response letter.

You may also be interested in...

VC Roundup: Three New Funds Close As Small, Early Financings Bounce Back

Even Series A rounds have been large during recent record-breaking years for biotech venture capital investment, but it looks like smaller financings for early-stage companies may be in the midst of a comeback. With VC firms closing new funds, that raises the question: Will the number of preclinical and Phase I financings increase?

Stockwatch: Fireworks Or Ballistic Missiles In Biotechnology?

Last week saw the NASDAQ Biotechnology Index (NBI) finish up 2.9%, outperforming a flat week for the broad market S&P 500 index. In the past six months this has been a reasonably rare event although it was often the case in the last biotech bull market that ended last summer. While much of the NBI's performance came from the relief rally on Friday, May 20, some commentators on social media were hailing it as the start of a recovery in biotechnology.

Acorda Picks Up Late-Stage Parkinson's Candidate With $363m Biotie Buy

Acorda Therapeutics Inc.'s president and CEO Ron Cohen has been dropping hints for some months that he was pursuing significant business development opportunities and the EU was his preferred hunting ground. Finally, on Jan. 19, Acorda said it has agreed to acquire Biotie Therapies Corp. of Finland for around $363m. Biotie has a Parkinson's disease drug candidate in Phase III which has a mechanism of action that has caused problems for other companies.


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts